Catalyst Wire Dossier Catalyst Wire Dossier

Antisense oligonucleotide therapy targeting FLVCR1 (PCARP)

unspecified · University of Colorado, Denver
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Antisense oligonucleotide therapy targeting FLVCR1 (PCARP), covering 2025-01-27 to 2025-01-27. Get the full timeline:

Most recent: Clinical Trial Update: Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1 [EARLY_Phase 1]

See pricing